Log in
Enquire now
‌

US Patent 8956830 Methods of cell culture

Patent 8956830 was granted and assigned to Momenta Pharmaceuticals on February, 2015 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Momenta Pharmaceuticals
Momenta Pharmaceuticals
Current Assignee
Momenta Pharmaceuticals
Momenta Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8956830
Patent Inventor Names
Rasheed Tijani0
Brett Belongia0
Holly Prentice0
Date of Patent
February 17, 2015
Patent Application Number
13829292
Date Filed
March 14, 2013
Patent Citations Received
‌
US Patent 12103960 VEGF traps and mini-traps and methods for treating ocular disorders and cancer
0
‌
US Patent 11753459 Anti-VEGF protein compositions and methods for producing the same
‌
US Patent 12012444 Anti-VEGF protein compositions and methods for producing the same
0
0
0
‌
US Patent 12077570 Anti-VEGF protein compositions and methods for producing the same
0
Patent Primary Examiner
‌
Jennifer Dunston
Patent abstract

Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8956830 Methods of cell culture

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.